• An interim analysis of the OA study is expected in Q1 2025
• Agreement with Region Östergötland regarding GMP production
• We keep the fair value at SEK 1.30 per share

Xintela recently extended the follow-up of the patients in the highest dose level group by six months in its OA study. The company expects an interim analysis from the 18-month follow-up in Q1 2025. Region Östergötland has assigned Xintela to develop and establish a GMP process for autologous skin cells for the treatment of burns. The deal is worth MSEK 3.6. Awaiting the license deal with EQGen Biomedical to materialise, we keep the fair value at SEK 1.30 per share. Read the full report here.

About Market Focus

The research report is prepared as part of Market Focus, Västra Hamnen Corporate Finance's commissioned research offering.

This is a press release from Västra Hamnen Corporate Finance AB. 
Web: vhcorp.se
Twitter: @vhcorp_se (https://x.com/vhcorp_se)